Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

SRL-172 has positive effects on response rate, survival and quality of life in NSCLC

Oct. 24, 2000

TroVax colorectal cancer vaccine approved for phase I/II

Oct. 23, 2000

Oncophage enters phase II sarcoma study; trial marks drug's seventh cancer indication

Oct. 23, 2000

Status of Dendreon's dendritic cell-based vaccines updated

Oct. 19, 2000

Maxamine inhibits sarcomas in preclinical study

Oct. 19, 2000

Roche begins E.U. launch for Herceptin

Oct. 11, 2000

Two dendritic/cancer cell fusion trials begun by Genzyme Molecular Oncology

Oct. 9, 2000

InterMune to commence Actimmune clinical trial in ovarian cancer

Oct. 4, 2000

FDA completes review of supplemental BLA for Rituxan

Oct. 2, 2000

O-Vax ovarian cancer vaccine awarded orphan drug status in U.S.

Sep. 29, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...